Drugs / Allogeneic bone marrow-derived MSCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02611167 | Nov 2017 → Sep 2019 | Parkinson disease | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic bone marrow-derived MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02611167 ↗ |
| Modality | Cell therapy | “mesenchymal stem cell (MSC) therapy” NCT02611167 ↗ |
| Route | Intravenous | “delivered intravenously” NCT02611167 ↗ |